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Abstract
Purpose Currently, information on the optimal approach of redo procedures for paroxysmal atrial fibrillation (PAF) is limited.
Radiofrequency ablation is the preferred technique, with reported success rates of 50–70% at 1–2 years, whereas only few reports
exist on redo cryoballoon (CB) ablations. We describe outcomes on a systematic approach of repeat procedures with a second-
generation cryoballoon (CB-2) after a successful index CB ablation.
Methods Cohort study of 40 consecutive patients with recurrent PAF (55% male), median CHA2DS2-VASc score 1 (IQR 0–3).
Per protocol, a staged variable balloon size strategy was followed with a different balloon size during the redo as compared to the
index procedure. Minimal follow-up was 12 months (median 17 months [IQR 14–39]).
Results Overall, 120 pulmonary veins (PVs) (75%) showed chronic isolation: 64% (41/64) for first-generation cryoballoon (CB-
1) and 82% (79/96) for CB-2 index procedures, respectively (p = 0.01). The overall mean number of reconnected PVs per patient
was 1.0 (40/40): 1.4 for CB-1 and 0.7 for CB-2 index procedures (p = 0.008). Phrenic nerve palsies (n = 7) resolved before the
end of the procedure. At 1 year, 70% of patients were free of recurrent AF. Inmultivariate analysis, the only independent predictor
of recurrence was the number of prior cardioversions.
Conclusions A systematic approach of repeat procedures with a CB-2 using a different balloon size than during the index CB
ablation is safe, with acceptable 1-year outcomes. Future comparative studies on the optimal redo technique and approach are
warranted to further improve rhythm control in AF.
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1 Introduction
Over the years, pulmonary vein isolation (PVI) has become an
accepted therapy for drug-refractory paroxysmal atrial fibrilla-
tion (PAF) [1, 2]. One-year success rates are about 70%, and up
to 20% of patients require a redo procedure [3–6]. At present,
little information is available on the optimal energy source and
approach during repeat procedures.
The vast majority of data pertains to radiofrequency (RF)
ablation, and success rates vary from 80 to 90% at 4–6 months
to 58–70% at 12–24 months [1, 2, 7–11]. As of yet, experiences
with cryoballoon (CB) ablation as a redo procedure after an
initial RF ablation are limited [11, 12]. With regard to a redo
CB ablation after a successful index cryoablation, only one report
has been published [13]. In that cohort, the first-generation CB
(CB-1) was used with a success rate of 60% 1 year after the redo.
Currently, the second-generation CB (CB-2) is used, known for
its enhanced surface cooling due to the double amount of nitro-
gen jets [14]. Notably, a recent paper on a series of redo proce-
dures demonstrated significantly lower numbers of reconnected
pulmonary veins in patients with a prior CB-2 procedure than in
patients with a prior RF ablation [7].
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With regard to the preferred approach in the redo setting,
the evidence for ablation on top of PVI versus PVI alone is not
uniform, and randomized data is scarce [1, 15]. In this context,
more information on redo procedures is warranted, and a re-
peat procedure with the improved second-generation balloon
might be a promising strategy. A first advantage concerns
safety [5], as only one transseptal puncture is required. In
addition, CB ablation is a more straightforward and fast pro-
cedure, and outcomes are less heterogeneous [16] and less
operator dependent.
A keymechanism of recurrent paroxysmal atrial fibrillation
after ablation is pulmonary vein (PV) reconnection, which
may reflect lack of efficacy in achieving transmurality and
long-lasting lesions [7]. It has been suggested that with CB
procedures, the (intensity of) contact of the balloon catheter
may not be equally good in all parts of the PVostium, appre-
ciating the high degree of variability in anatomy and the uni-
form design of the balloon [10, 17]. This was the rationale of
the so-called double-balloon strategy, performed during index
procedures for persistent AF.With use of two different balloon
sizes during one procedure, a success rate of 70% at 1 year
was observed [17].
This strategy aimed to achieve optimal anatomical PV ab-
lation, due to anatomical contact at a different level of the
pulmonary vein ostium (either more ostial, 23 mm, or more
antral, 28 mm). In addition to PVI, this approach would pro-
vide additional substrate modification [18]. Finally, this
double-balloon ablation, with either more focus towards the
ostium, or towards the antrum, may provide optimal coverage
of the area of the ganglionated plexi, with the majority located
in close proximity of the PV-LA junction [19–28].
In the abovementioned context, we systematically per-
formed each redo procedure with a different balloon size as
compared to the first procedure. As for procedural character-
istics, we describe the proportion of pulmonary veins with
chronic PV isolation and the total number of reconnected
PVs per patient. With regard to clinical outcome, we report
safety and freedom of AF at 12 and 24 months.
2 Methods
2.1 Patient cohort
Patients underwent a redo CB ablation for ECG and/or Holter-
documented recurrences of paroxysmal AF after an initial CB
procedure with successful PVI. Paroxysmal AF was defined
as episodes of irregular atrial arrhythmia lasting longer than
30 s and terminating within 7 days (spontaneously or with
cardioversion). Persistent AF was defined as episodes that last
longer than 7 days [1].
To ensure a minimal follow-up evaluation of 1 year, we
studied all redo procedures performed with the CB-2 between
October 2012 and November 2016 at the Radboudumc,
Nijmegen, The Netherlands. Patients younger than 18 years
were not eligible for ablation of AF at our institution, neither
were patients with an estimated life expectancy < 1 year.
Patients with severe comorbidity, left ventricular ejection frac-
tion < 35%, or more than grade 2 valvular disease were not
eligible for the staged variable balloon size protocol. Given
the observational design of the study, written informed con-
sent was not necessary to obtain according to the DutchAct on
Medical Research involving Human Subjects.
2.2 Periprocedural management
A computed tomography (CT) scan was performed for three-
dimensional anatomy of the PVs. Anatomical variants (i.e.,
common ostium) were also eligible to undergo CB proce-
dures. All patients used oral anticoagulation therapy prior to
the procedure.
In case of vitamin K antagonists (VKAs), an uninterrupted
anticoagulation strategy was followed with an international
normalized ratio (INR) target range of 2.0–3.0 [29]. In case
of non-vitamin K antagonist oral anticoagulants (NOACs), we
adopted an interrupted regimen, with a pre-procedural
NOAC-free interval of 12–24 h. Oral anticoagulation was
continued for 3 months, after which life-long treatment was
based on the CHA2DS2-VASc score. Antiarrhythmic drugs
were continued for at least 3 months (blanking period) after
the procedure.
2.3 First ablation
Procedures were performed under general anesthesia or con-
scious sedation, with transesophageal echocardiography
(TEE) to exclude thrombi in the left atrium. After two punc-
tures in the right femoral vein, a steerable decapolar diagnostic
catheter was positioned in the coronary sinus (CS). Access to
the left atrium and PVs was obtained by performing a single
transseptal puncture using the 8,5-French (SL0, St. Jude
Medical) under fluoroscopic guidance and TEE imaging.
Directly thereafter, an initial bolus of 70 IU/kg heparin was
administered, and the ACT was determined at 20-min inter-
vals to ensure a target activated clotting time (ACT) > 300 s.
All ablations were performed with a CB (Medtronic,
Minneapolis, MN, USA) in combination with the 12-French
steerable sheath (Medtronic, Minneapolis, MN, USA). During
the first procedure, isolation of the PVs with disappearance of
real-time potentials was confirmed by absence of reconnection
after adenosine. All the PVs were mapped with an inner lumen
mapping catheter (ILMC) (Achieve Mapping catheter 20 mm
Arctic Front, Medtronic, Minneapolis, MN, USA). Vessel oc-
clusion was considered optimal when selective contrast injec-
tion showed total contrast retention. Every PV was treated with
at least two applications. The freeze cycles were 240 s for CB-1
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and 180 s for CB-2. Balloon size of the CB was either 23 or
28 mm. In case of an RSPV diameter > 21 mm at CT imaging,
we opted for a 28-mm balloon during the index procedure to
reduce the risk of phrenic nerve (PN) palsy [30]. To early detect
PN palsy, PN pacing was performed during applications on the
right-sided veins, with the decapolar catheter from the CS po-
sitioned in the superior vena cava (SVC). Before the first appli-
cation, capture was determined with palpation on the abdomen
of the hemidiaphragmatic excursion. The PN pacing was
started when the balloon temperature reached − 30 °C (20 mA
at 1.0 ms pulse width at a cycle length of 1200 ms). When
diminished diaphragm movements were noticed, the ablation
was interrupted with immediate balloon deflation [31].
The day after the procedure, a protocol-driven transthoracic
echocardiogram (TTE) was performed to exclude pericardial
effusion after which the patient was discharged.
2.4 Redo procedure
All redo procedures were performed with CB-2, and the setup
of the second ablation procedure was similar to the initial
procedure except for the size of the balloon. Patients with a
23-mm balloon in the first procedure underwent their redo
procedure with a 28-mm balloon and vice versa.
In general, this particular redo strategy ensures a different
anatomical match between the balloon and the ostium of the
pulmonary vein than during the index procedure, which may
have two advantages. First, it allows for pulmonary vein iso-
lation at a different level, either more ostial (23 mm) or more
antral (28 mm) than during the index procedure. In fact, de-
spite optimal occlusion during the index procedure, the cir-
cumferential intensity of the lesionmay not have been equal in
all parts of the vein due to anatomical reasons, which may
have contributed to reconnection. This was the key argument
for the variable balloon size strategy.
A second advantage is that the use of two different balloon
sizes may contribute to a more comprehensive anatomical
ablation. The 28-mm balloon would also provide additional
antrum modification, which has been implicated as part of the
success of cryoballoon ablation [18]. On the other hand, on
top of PVI at a different level, a 23 mm balloon was expected
to provide a higher intensity ablation at the level of the ostium,
which may have better impact on the GPs given their prefer-
ential localization at the PV LA junction [19].
When mapping of the PV showed reconnection, two appli-
cations were performed. In the absence of reconnection our
protocol specified a single freeze, appreciating the role of
fractionated ostial potentials as a contributor to recurrences
[9, 32], and the abovementioned impact of additional substrate
ablation and GP modification [18, 25]. An additional argu-
ment was that, reconnection may have gone undetected in
some cases, as there was no systematic administration of aden-
osine prior to the redo. Moreover, despite the good correlation
between the ILMC (Achieve) and the Lasso, there is no flaw-
less 1:1 correspondence [33].
2.5 Follow-up and endpoint
Follow-up was systematically collected and included (1) pro-
tocol-driven, intensive Holter monitoring, (2) systematic out-
patient follow-up, and (3) symptom-driven clinical follow-up.
Holter follow-up comprised 6-day Holter monitoring at 6 and
12 weeks, and at 6 and 12 months after ablation. Successive
visits at the outpatient clinic were scheduled 1–2 weeks after
each of the respective Holter recordings, and each visit includ-
ed a resting ECG and physical examination. In addition, all
patients were encouraged to contact the hospital in case of
palpitations to incorporate ECG-documented recurrences ob-
served during ER visits and admissions.
As endpoints of this study, we assessed the proportion of
patients without AF recurrence at 12 and 24 months, appreci-
ating a blanking period of 3 months after the procedure.
2.6 Statistical analyses
Categorical variables are presented as proportions, and con-
tinuous variables are presented as means ± standard deviations
(SD) or medians with interquartile ranges.
Comparisons between categorical variables were made
with chi-squared tests or Fisher’s exact tests. Furthermore,
we used Kaplan-Meier analyses for the estimation of AF re-
currence at 2 years of follow-up. Potential risk factors for AF
recurrence on univariable analyses (p < 0.10) were assessed in
a multivariable model, using binary logistic regression. A two-
tailed p value < 0.05 was considered statistically significant.
We used SPSS version 22.0 (SPSS, Inc., Chicago, IL, USA).
3 Results
3.1 Study group and baseline characteristics
During the study period, there were 543 ablations which
included 86 redo procedures (16%). Of these, 40 were CB-
2 procedures for recurrent paroxysmal AF using the vari-
able balloon size strategy (Fig. 1). Mean age of the study
population was 59 years (± 9.5 years) and 22 (55%) were
male. Patients had a median CHA2DS2-VASc score of 1
(IQR 0–3) and a median left atrial volume index of
33 mL/m2 (IQR 24–37). The index procedure was per-
formed with a CB-1 in 16 patients (40%), and a 28 mm
balloon was used in 31 patients (78%) during this initial
procedure. Median time between the initial and redo proce-
dure was 13 months (IQR 7–23). In anticipation of the redo
procedure, 53% (n = 21) of patients were on class I or III
antiarrhythmic drugs (Table 1).
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3.2 Procedural information
Themedian procedure timewas 65min (IQR 60–85min) with
a median fluoroscopy time of 18 min (IQR 12–21 min), as
displayed in Table 2. After gaining access to the left atrium, all
PVs were first mapped using the ILMC (Achieve).
Durable electrical PVI was observed in 120 of 160 veins
(75%). Among the patients with CB-1 in the initial procedure,
the proportion of chronic PVI was 41/64 (64%), in contrast to
79/96 (82%) in patients with a CB-2 used in the initial proce-
dure (p = 0.01). The corresponding numbers of reconnected
veins per patient were 1.0 (40/40) in the entire cohort, 1.4
for patients with an initial CB-1 procedure and 0.7 for patients
with an initial CB-2 procedure (p = 0.008).
In total, 48 (60%) superior PVs were isolated, as compared
to 72 (90%) of the inferior PVs (p < 0.001). When comparing
the left veins (LSPVand LIPV) and the right veins (RSPVand
RIPV), a total of 54 veins (68%) were isolated at the left side
and 66 (83%) at the right side (p = 0.04). The numbers of
individual isolated veins were 22 (55%) for the LSPV, 32
(80%) in the LIPV, 26 (65%) in the RSPV, and 40 (100%) in
the RIPV.
In total, 12 patients (30%) showed durable isolation in all
veins. Importantly, after CB-1 ablation in two patients (13%),
all PVs appeared isolated, as compared to ten patients (42%)
after an initial CB-2 procedure (p = 0.08).
3.3 Long-term success rates
All patients had a minimal follow-up of 12 months, and me-
dian follow-up was 17 months (IQR 14–39). At 1 year, 28
patients (70%) were free of AF recurrence (Table 3). Among
the 12 patients with AF recurrence, 10 (83%) were detected as
part of a clinical presentation at the outpatient clinic or chest
pain unit with documented AF. In three cases, recurrent pal-
pitations were documented as AF by protocol-driven Holter
monitoring. AF-free survival at 2 years was 56%. In the mul-
tivariable analysis, only the number of previous electrical
cardioversions was independently associated with AF recur-
rence at 1 year (hazard ratio 1.47, 95% confidence interval
1.03–2.10).
3.4 Complications
No major periprocedural complications (thromboembolic
events, tamponades, major bleedings, atrioesophageal fistu-
las) occurred. No complications due to the vascular access
Abbreviations: CB-2 = second generation cryoballoon; PAF = paroxysmal atrial  
fibrillation; CBA = cryoballoon ablation  
Fig. 1 Flowchart of study population
Table 1 Baseline demographic and clinical characteristics
Baseline characteristic Study patients
(n = 40)
Age in years, mean (± SD) 58.7 (9.5)
Male gender 22 (55%)
Body mass index in kg/m2, median (IQR) 26.3 (23.6–29.4)
Months since AF diagnosis, median (IQR) 62 (31–127)
Number of cardioversions, median (IQR) 1 (0–3)
CHA2DS2-VASc score, median (IQR) 1 (0–3)
Hypertension 21 (53%)
Coronary artery disease 0 (0%)
Diabetes mellitus 1 (3%)
Previous stroke/transient ischemic attack 1 (3%)
Peripheral artery disease 1 (3%)
Glomerular filtration rate < 60 mL/min 1 (3%)
Left ventricular ejection fraction in %,
median (IQR)
61 (60–61)
Left atrial volume index ≥ 34 mL/m2 18 (45%)
Months since first procedure, median (IQR) 13 (7–23)
Balloon generation at index procedure
First-generation balloon 16 (40%)
Second-generation balloon 24 (60%)
Balloon size at index procedure
23 mm balloon 9 (23%)
28 mm balloon 31 (78%)
Oral anticoagulation therapy
Vitamin K antagonist 30 (75%)
Non-vitamin K oral anticoagulant 10 (25%)
Current use of antiarrhythmic drugs
Class I agent 12 (30%)
Class III agent 9 (23%)
Previously used antiarrhythmic drugs
Class I agent 13 (33%)
Class III agent 14 (35%)
SD standard deviation, IQR interquartile range, AF atrial fibrillation
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were noticed. Transient PN palsy was seen in seven patients
(18%) during the redo ablation, of which two patients were
treated with a 23 mm CB during the redo procedure.
Immediate balloon deflation was done when PN palsy was
noticed. Despite the interrupted freeze, all the PVs were prov-
en isolated. All PN palsies recovered before the end of the
procedure.
4 Discussion
To our knowledge, this is the first report on the efficacy and
safety of a systematic strategy of repeat procedures with a CB-
2 after an initially successful PVI with CB ablation. With 1-
and 2-year success rates of 70 and 56%, respectively, outcome
is acceptable and procedural safety was good. We identified
the number of previous cardioversions as a predictor of AF
recurrence.
4.1 Redo strategies—rationale and evidence
Information on the optimal technique for a repeat procedure for
recurrent AF is scarce and approaches vary, as do the reported
success rates [1, 2, 6–12]. As of yet, the experience and available
evidence for redo procedures has been in favor of RF ablation. A
randomized comparison between CB-1 and RF as repeat proce-
dure after an index RF procedure resulted inmarkedly better AF-
free survival after repeat RF [11]. Appreciating the 40–60%
recurrence rates after a redo, several groups have studied an
approach of more extensive ablation and suggested better out-
comes, but randomized evidence does not corroborate [1, 2, 15].
With the introduction of the CB-2, rates of up to 75–90%
durable PVI have been reported [34], significantly better than
observed with the CB-1 [35], and also higher than with RF
ablation [7, 36]. Recently, a first series of CB-2 redo procedures
has been described after an index RF procedure, with reported
rates of durable PVI of 54% at the time of the redo, and a 1-year
success rate of 83% [12]. These observations support further
study on CB-2 ablations as a repeat procedure, as it could be a
promising safe [5], straightforward, and fast strategy, with more
reproducibility in outcomes than RF ablation [16].
In follow-up on the rationale of previous work, we defined
a redo protocol with the staged use of two different balloon
sizes as we hypothesized that this would allow for different
(intensity of) contact during pulmonary vein occlusion.
Appreciating there was total pulmonary vein occlusion and
successful isolation during the index procedure, we now
aimed for pulmonary vein isolation at a different level, either
more ostial (23 mm) or more antral (28 mm). This was the key
argument to use a larger, or smaller, balloon during the redo.
Procedures performed with the 28 mm balloon were ex-
pected to result in additional substrate modification, which
could be of added value, in terms of posterior wall antrum
ablation and potentially targeting rotors and non-PV triggers
[18, 37–39].
Finally, with this redo approach, we aimed to achieve a
more comprehensive anatomical ablation of the area where
the (networks to the) GPs are located [19], with the intention
to focus the ablation more towards the ostium (23 mm) or the
antral area (28 mm) of the pulmonary vein. As initiation and
maintenance of AF is also affected by GPs [20–24, 28], this
approach may provide additional benefit for AF-free survival
[25–27]. Appreciating the abovementioned rationale and the
higher force of CB-2 balloons, we adopted this systematic
approach of redo procedures with a CB-2 balloon using a
different balloon size as compared to the index CB procedure.
4.2 Repeat procedure—durable PV isolation
Our overall proportion of 75% chronic PVI was a composite
of 64 and 82% for first- and second-generation cryoballoon
index procedures, respectively, which confirms the high
Table 2 Procedural characteristics of repeated catheter ablations
Procedural characteristic Study patients
(n = 40)
Procedural time in minutes, median (IQR) 65 (60–85)
Fluoroscopy time in minutes, median (IQR) 18 (12–21)
Number of reconnected pulmonary veins
0 12 (30%)
1 19 (48%)
2 6 (15%)
3 3 (8%)
4 0 (0%)
Reconnected vein
Left superior pulmonary vein 18 (45%)
Left inferior pulmonary vein 8 (20%)
Right superior pulmonary vein 14 (35%)
Right inferior pulmonary vein 0 (0%)
IQR interquartile range
Table 3 Recurrence of atrial fibrillation at 1 and 2 years after redo
ablation
1 - year recurrence-free survival 70%a (28)
Documented recurrence 30% (12)
ECG with clinical presentation 25% (10)
Holter registration 8% b (3)
2 - year recurrence-free survival 56%c
aAll patients had at least one year follow-up
b In one case, detection both by routine Holter monitoring and by clinical
presentation at the Chest Pain Unit
c Event rates by Kaplan Meier, median follow-up was 17 months (IQR
14-39)
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durable isolation with the latter, with rates comparable to pre-
vious reports [7–10, 13, 32, 34–36]. Remarkably, in our series,
the right inferior PV had the highest rates of durable isolation,
which contrasts previous observations [7, 9, 32, 36]. Durable
isolation in all PVs was observed in about a third of patients,
in line with previous reports. Notably, in the absence of recon-
nection, fractionated ostial potentials have been implicated as
a contributor to recurrences, with several groups performing
additional ablation in the setting of a redo [9, 32]. Moreover,
the Achieve catheter has a good but not flawless 1:1 corre-
spondence with the Lasso catheter and electrical activity may
have gone undetected in some cases [33]. Finally, there was no
systematic administration of adenosine at the start of the re-
peat procedure.
In the aforementioned context, and appreciating the fact
that all patients had the clinical presentation of recurrent par-
oxysmal AF, our protocol specified a single freeze in PVs that
showed no signs of reconnection. Interestingly, complete iso-
lation at the start of the repeat procedure was not a predictor of
higher rates of AF recurrence, which may be an indirect clue
that also other mechanisms than pulmonary vein isolationmay
be implicated in the process of recurrences.
4.3 Repeat procedure—AF-free survival
Considering the outcomes after an index ablation procedure
[5, 6], the observed 1- and 2-year success rates of 70 and 56%
are very acceptable for repeat procedures and are higher than
the rates reported for redo procedures with a CB-1 after an
index CB ablation [13]. Similar considerations hold true for
the AF-free survival rates achieved with a CB-2 procedure
after an index RF ablation [12]. The markedly better acute
and long-term durability of PV isolation with the CB-2 may
be one of the explanations for the improved rates we observed.
At present, the majority of evidence on outcome after re-
peat procedures pertains to RF procedures. Reported success
rates of RF redo procedures after an index CB-1 are 86% at
6 months and 73% at 2 years [8, 10]. As for index procedures
with a CB-2, a repeat procedure with RF has been reported to
result in 4–6-month success rates of 69–89% and a 1-year
result of 83% [7–9].
4.4 Implications
Our observations of 82% chronic PV isolation with the CB-2,
and the acceptable success rates after the repeat procedure
provide a first indication of the potential to perform redo pro-
cedures for (paroxysmal) AF with the second generation
cryoballoon. Due to the variety in reported approaches, study
populations, and chosen time points to report outcomes, cau-
tion is warranted with regard to comparative conclusions with
RF, which calls for head to head comparisons.
Whereas the present protocol was rather straightforward, a
systematic approach with adenosine, Lasso measurements,
and more detailed mechanistic studies could have provided
more insight into to underlying mechanisms of recurrence.
More detailed studies are warranted to optimize (longer-
term) outcomes after repeat procedures, and assess whether
and how the focus should shift towards approaches focused
on additional substrate modification and/or ganglionated plexi
ablation on top of PVI [1, 2].
4.5 Limitations
Although this represents the first systematic cohort of second
generation cryoablation redo procedures after an index
cryoballoon ablation, our sample size is limited and results
only pertain to patients with recurrent paroxysmal atrial fibril-
lation treated in a medium-volume center with experienced
operators [40]. In lack of a control group, it is uncertain how
much the use of a different balloon size during the second
procedure contributed to the outcomes. Before implementa-
tion on a larger scale, our findings require confirmation.
5 Conclusions
This strategy of repeat ablation with a second-generation
cryoballoon, using a staged variable balloon size approach,
is safe and results in acceptable outcomes at 1 and 2 year
follow-up.
With the high durable rates of chronic pulmonary vein
isolation achieved with the second generation cryoballoon,
randomized studies on the optimal technique for repeat proce-
dures are eagerly awaited.
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